What topics are we interested in publishing in Experimental Biology and Medicine?
The Anatomy/Pathology section invites reports of original research that provide novel insights integrating structure and function with regard to biology and medicine. A primary goal is to attract hypothesis-driven or discovery-based investigations that focus on - and test - mechanistic or fundamental questions involving human or animal anatomical structures. For example, studies that correlate cellular and molecular biology with basic or pathological anatomy with accompanying biochemical, pharmacological and or behavioral analyses to support functional significance are invited. Quantitative rather than descriptive, qualitative evidence is preferred, and data need to be evaluated by rigorous statistical methodology. Authors should keep in mind that scientific merit and clear communication will be primary factors evaluated by the referees. Of particular interest to this section are papers that relate research findings to the normal and abnormal human condition including translational research using human cells and tissues, as well as models (single cells or multicellular organisms) of human disease. Manuscripts only reporting new techniques or application of techniques to new areas are discouraged, as are descriptive studies or case reports.
The Artificial Intelligence/Machine Learning Applications to Biomedical Research section invites high quality manuscripts of original research and review articles on applications of artificial intelligence including machine learning and deep learning in biomedical research. A primary goal is to accelerate and promote applications of both the state-of-the-art and emerging machine learning and deep learning techniques to advance biomedical research. Original research articles on development of new algorithms, software tools, and infrastructures of machine learning and deep learning for effectively answering scientific questions in biomedical research are the focus. Original research articles that describe applications of the state-of-theart machine learning and deep learning algorithms and software tools to address specific scientific questions in biomedical research are welcome. Comprehensive and minireview articles summarizing the progress of machine learning and deep learning as well as their applications in a broad or narrow field in biomedical research are particular interest to this section. This section also publishes brief communications reporting new databases and data sources that can facilitate development and applications of machine learning and deep learning models in biomedical research. Scientific merit and technical soundness will be the major metrics in evaluating manuscripts. The effective communication of experimental methods and results including originality, clarity, quality and accuracy of the text, figures and tables is important to editorial decisions.
The Biochemistry and Molecular Biology section seeks manuscripts describing original research and minireviews that will make novel and substantive contributions to elucidating the molecular and cellular basis and/or mechanisms of cell function or disease. There are a number of areas of particular interest. One is in the rapidly expanding field of non-coding RNAs. Studies are sought on long non-coding RNAs (lncRNA), microRNAs (miRNA), small interfering RNAs (siRNA) and circular RNAs (circRNA), their role and mechanism of action in many cellular processes such as gene and epigenetic regulation, chromatin dynamics, endoplasmic reticulum stress, apoptosis, cell proliferation and migration; their important role in various disease processes such as cancer development, progression and metastasis; and their therapeutic potential and use as biomarkers for diagnosis of diseases. Another area of specific interest is in studies which will advance our knowledge and provide new insights on proteins associated with the nucleoskeleton and cytoskeleton such as tubulin, lamin, actin, myosin, and spectrin, on their Section Descriptions (October, 2022) Page 2 interactions with each other, with the LINC (linker of nucleoskeleton and cytoskeleton) complex in mediating signaling between the nucleus and cytoplasm and in regulation of multiple cytoplasmic and nuclear processes. Of importance are new developments on how, mechanistically, defects or deficiencies in these proteins affect nuclear movement and architecture, cellular migration, mitosis, cell adhesion, cell-cell contact, and biomechanical functions of the cell, and lead to diverse pathological processes such as the laminopathies, DNA repair disorders, cancer invasion and metastasis, pathological cardiac remodeling, and impaired wound healing. Another area of specific interest is research on new advances in the fields of DNA repair and genomic instability, on the proteins associated with the repair processes and their mechanism of action, on the importance of these proteins in chromosome stability and telomere function, and the disorders associated with defects or deficiencies in these proteins. These are examples of specific areas of interest but are neither exhaustive nor mutually exclusive. It is important that the manuscripts submitted are well written. EBM is a multidisciplinary journal; therefore, the central points need to be clearly communicated and their impact stressed. Rigorous statistical analysis of the data must be carried out. The quality and clarity of figures and tables is also important.
The Bioimaging section invites original manuscripts and review papers in all fields of biomedical imaging including the development and applications of novel technologies for molecular, metabolic, ultrastructural, anatomical, and functional imaging of human and animals. Areas of interest encompass from whole organism, to tissues and cells, particularly including research in the field of morphological and functional mapping of the brain of human and animals with X-ray computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), transcranial magnetic stimulation (TMS), magnetoencephalography (MEG), electroencephalogram mapping, ultrasound imaging, photoacoustic imaging, optical coherence tomography, multiphoton microscopy, and other emerging technologies. Papers that focus on the investigations and studies in the following subjects and fields are welcome: (1) Investigation of the morphological and functional architecture of single organs, tissues, and cells that provide novel and interesting results on the relation between structure, and function either in physiological or pathological conditions; (2) novel non-invasive methodologies for the investigation of single organs, tissues, and cells with potential applications in the diagnostic or therapeutic domain; (3) research that combines multiple investigative approaches, such as genetics and imaging, or imaging with pharmacological probes; (4) wtudies on the in vivo imaging of the molecular mechanisms that underlie cognition and mental activity in healthy conditions as well as in the presence of neurological and psychiatric disorders and of the effects of pharmacological and non-pharmacological treatments. Manuscripts will be reviewed on the basis of scientific merit and respect of internationally accepted ethical standards for animal and human research. Submission of purely clinical studies is discouraged. Single case reports will be considered only if they may represent a significant advancement in the comprehension of pathophysiological mechanisms
The Biomedical Engineering section aims to publish original research articles and minireviews that integrate novel engineering methods with biology and medicine. Such examples include novel nanotechnology platforms for biosensing, imaging disease-specific biomarkers, and therapeutic delivery; advanced imaging technology (e.g. MRI, PET) for quantitative analysis of pathophysiology; novel biomaterial scaffold and controlled release technology for tissue engineering applications; and integrated imaging and therapeutic systems (Theranostics) for image-guided therapy. Interdisciplinary approaches bridging engineering sciences with biology and medicine are strongly endorsed, and there is reduced interest in traditional, well-defined areas of research (e.g. biomedical transducers) unless unique designs Section Descriptions (October, 2022) Page 3 that will lead to unprecedented biological discoveries are evident. For minieviews, we strongly encourage thought leaders in the field to discuss future opportunities in the emerging key technologies, and how they may benefit biology and medicine. For original research articles, we emphasize the scientific merit as well as the artistic presentation for effective communication of the scientific data.
The Bionanoscience section is a forum for original research and minireviews on topics at the interface between nanotechnology and the biological or medical sciences: Nanotechnology is broadly defined as research and technology development at the atomic, molecular, or macromolecular levels in the length scale of approximately 1-100 nanometer range. Of particular interest are manuscripts describing synthetic or natural nanostructures that have innovative applications in the treatment or diagnosis of disease or in the advancement of basic biological research. This encompasses topics in the field of nanomedicine. While no less important, the development and application of medical devices and instrumentation involving nanotechnology is not emphasized in the Bionanosciences section and manuscripts in this area might be suited for the Biomedical Engineering section.
The Cell and Developmental Biology section welcomes manuscripts that encompass mechanisms which regulate cellular structure and activity, particularly as they relate to developmental processes. Examples of developmental processes include control of early embryogenesis and mechanisms that determine cellular lineage and fate. The use of model lower organisms such as yeast, Drosophila and Caenorhabditis elegans are most welcome, as are vertebrate models of differentiation and development. Manuscripts that elucidate basic developmental mechanism(s) which are then evaluated using in vivo systems are encouraged. At the cellular level, the Cell and Development section will entertain manuscripts that examine basic mechanisms of cellular activity such as regulation of cell division, cell cycle, cellular responses to DNA damage, cell polarity, adhesion, and migration. Manuscripts that use single cell analyses of nucleic acids and proteins that provide insight into cellular and developmental mechanisms are also welcome. The above examples represent the types of research areas that will be considered by this section, but the list should not be considered as all inclusive.
The Clinical Trials section invites original research or minireview articles describing research conducted in human-subjects. Publications in this section may include reports from first-inhuman research, other Phase I research, or Phase II, III, or IV research. In addition to interventional trials, the section invites population-based studies including prospective or retrospective observational studies. Original research detailing study design or trials in progress are also welcome. Biomarker based research is appropriate if biospecimens were collected from or directly relating to treatment of patients. Meta-analysis studies, or review articles focusing on clinical trials data are also welcome. Original research manuscripts are expected to be of high scientific merit, but not limited to “positive” versus “negative” trial results. Minireviews are expected to be a comprehensive treatment of a clinical trials topic, and both meta-analyses or high-quality descriptive reviews will be accepted.
The Endocrinology and Nutrition section welcomes the receipt of highly impactful manuscripts on any topic relevant to endocrinology or nutrition. Of particular interest are original research articles and timely reviews on topics that would be of widespread interest. In the field of endocrinology, we welcome novel findings related to the actions of hormones on their target tissues and new findings related to clinical endocrine disorders. These include but are not limited to findings regarding hormone receptors and their signaling pathways, developmental changes in endocrine function, identification or clarification of hormone functions, Section Descriptions (October, 2022) Page 4 targeted deletions of genes important to endocrine function, and nutritional factors impacting endocrine function and diseases of the endocrine system. In the area of nutrition, original manuscripts on metabolism, nutrigenomics, nutritional biochemistry, food safety, clinical nutrition, nutritional impacts upon the risk of developing or the treatment of specific diseases (e.g., cancer, diabetes, Alzheimer’s disease), the microbiome, and nutrition/aging/health are particularly welcomed. However, there will be reduced interest in articles addressing eating disorders, food policy, and sports nutrition.
The Environmental Health/Biomarkers/Precision Medicine section invites reports of original research articles and minireviews that provide novel information on biomarkers with an emphasis on their impact on precision medicine. A primary goal is to identify and examine biomarkers of effect, disposition and susceptibility that prove useful in assessing the safety and efficacy of drugs and biologics as well as the safety of food. Investigations focused on technologies enabling precision medicine in clinical application and biomarker qualification are especially relevant to the drug development process and are welcomed for submission to this section. Submitted manuscripts may include information on the development of innovative biomarkers for application to clinical assessments and to medical product development as well as those relevant to other scientific areas concerning product safety (e.g., foods and devices). The goal is to accelerate development, refinement, and precision application of medical products; assess the safety of food; and provide information on the toxicity of tobacco products. For the reviews, we strongly encourage thought leaders in the biomarker field to discuss emerging and mature biomarkers as they travel the development and qualification process and how they may benefit public health. For original research articles, scientific merit will be emphasized as well as the effective communication of the scientific data including clarity, quality and accuracy of the text, figures and tables, and clarity of methods, experimental design, and statistical analyses.
The Genomics, Proteomics and Bioinformatics section invites original research papers and minireview articles in genetics, genomics, epigenomics, metagenomics, proteomics, metabolomics, and related areas of bioinformatics. We are also interested in contributions that describe new workflows and methods of data processing, analysis, diagnosis, and integration across scales – from sequence variants to clinical, social and economic impact.
The Immunology/Microbiology/Virology section has a broad remit and welcomes the receipt of manuscripts reporting novel research findings and minireviews on each of these aspects of experimental biology and medicine. Studies with clear translational relevance are particularly encouraged, such as investigations of bacterial/viral diseases, cancer immunology, transplantation medicine, autoimmunity, allergy, development of vaccination strategies and novel immunotherapies. There is reduced interest in articles on fundamental topics such as the taxonomy of microorganisms, unless innovative research tools and concepts are employed to address previously intractable questions. While emphasizing the importance of scientific content (quality and novelty), our editorial policy recognizes the importance of clear and lucid presentations as reflected in the eloquence of the scientific language and the clarity and quality of the figures used for data or conceptual presentations.
The Mechanisms of Aging section welcomes original research and minireviews covering a broad aspect of aging research from the basic to applied science, including human translational (clinical) studies. We are particularly interested in studies investigating the mechanism of aging using human samples as well as model organisms (from unicellular organism to vertebrate and non-vertebrate organisms). Studies using in vitro (cell culture) system are also welcome. The Section Descriptions (October, 2022) Page 5 broad definition of the mechanism of aging includes (1) the mechanism of lifespan determination, (2) the mechanism of age-dependent alteration of cellular- or/and tissue-function, and (3) the mechanism of age-dependent onset/progression of diseases. This section also welcomes the reports investigating interventions in aging and age-dependent diseases as these studies provide new insights regarding the aging mechanism. We will consider various types of study methods including biochemistry, molecular biology, cell biology, genetics, pathology, nutrition science, sports medicine, proteomics, genomics, metabolomics, biostatistics, theoretical model analysis and other scientific approaches investigating the mechanism of aging and lifespan determination.
The Neuroscience section welcomes reports on original, high quality, research in neuroscience that provide new fundamental insights into the workings of the nervous system in health and disease. A primary area of interest is hypothesis driven research that seeks to identify fundamental questions about how the nervous system develops, maintains homeostasis, contributes to sensory and motor information processing and control, performs higher cognitive functions, and the processes that underlie these functions. Examples of underlying processes include: regulation of gene expression by cells of the nervous system; neurovascular coupling; synaptic and membrane function; properties of networks of neurons and glia; learning and memory; intra- and intercellular signaling; and the interaction of these processes in the nervous system with other systems such as the cardiovascular, endocrine and immune systems, as well as in metabolic control and homeostasis. Studies on the effects of aging and a wide variety of neurological and psychiatric diseases on these processes, including the identification of new potentially therapeutic targets and processes, as well as the delineation of mechanisms for novel diagnostic approaches are of interest. In addition to such hypothesis driven research, original studies that are discovery based, including screens and identification of molecular components of these processes and diseases, if framed within the context of fundamental questions about nervous system development, function and dysfunction are also welcome. Studies of the effects of incompletely characterized compounds or mixtures of substances on nervous system development or function, whether natural or synthetic are not appropriate. Likewise, studies that are primarily targeted at additional uses of clinical procedures are not appropriate.
The Pharmacology and Toxicology section covers a wide range of topics and this section strives to reflect that diversity. The section will emphasize original work and minireviews that elucidate drug action and underlying mechanisms, new druggable targets, or unusual drug responses (e.g., due to polymorphisms and drug interactions), which contribute significant knowledge to pharmacology or toxicology. Submissions are expected to meet the standards of pharmacological and/or toxicological investigation. For example, manuscripts should include dose-response analysis, rather than using a single dose, and seek to demonstrate cause and effect relationships, rather than only presenting correlational findings. Appropriate control groups, such as drug vehicle-treated and drug-exposed normal groups, should be included. While manuscripts in all areas of pharmacology and toxicology are welcomed, studies on herbal medicines or plant extracts with unknown components or mixtures of active ingredients are generally not appropriate unless exceptional new activity has been discovered. Manuscripts reporting a known drug action on previously unstudied cells or tissue are generally also not appropriate without strong justification of the importance of the study.
The Physiology and Pathophysiology section welcomes high-quality manuscripts reporting innovative studies that address normal function and/or impact of diseases and treatments on whole organisms, organ systems, organs, cells, organelles, membranes, and biomolecules. Section Descriptions (October, 2022) Page 6 Reviews of current topics of interest within the broad scope of physiology and pathophysiology also are welcomed. Examples of topics that fall within this section’s scope include: membrane ion transport and electrophysiology; autonomic control of internal organs; neuro-hormonal signaling mechanisms and their impact on cells and organs; adaptation and maladaptation of internal organs to environmental stresses; mechanisms of ischemic or inflammatory injury of internal organs and novel strategies to prevent such injury; mitochondrial support of cellular function and mediation of cell death vs. survival; physiological regulation of glomerular filtration and renal tubular electrolyte transport; neuroendocrine mechanisms of hypertension; mechanisms of excitotoxicity in brain neurons and its treatment; integrated regulation of cardiopulmonary function during exercise or hypoxia; and the impact of diabetes, volume and electrolyte disorders, immune dysfunction and other disease processes on internal organs, their constituent cells and their functions. The criteria for evaluating manuscripts are: novelty and potential impact of the work; clarity, quality, accuracy and originality of the text, figures and tables; how effectively the methods, experimental design and statistical analyses address the hypotheses; and how well the results support the conclusions.
The Population Health section addresses the need to understand and address the social determinants of health is critical. Social determinants of health data such as income, educational level, employment, language, and place where individuals live can enhance of hinder health. Efforts to address social determinants of health data can help improve people’s health on a local level. Population health interventions include interventions, programs and policies in public health and health services research to change the population distribution of risk and enhance improvement of the health and wellbeing of patients experiencing socioeconomic disadvantages. The journal invites original articles, systematic reviews, case studies, and commentary to describe population health assessments, targeted interventions, programs, and policies that influence the enhancement of good health and well-being of the individuals, families, and the communities they live in.
The Stem Cell Biology section seeks original articles and minireviews that describe fundamental investigations in the rapidly expanding field of stem cell biology. Manuscripts on all aspects of stem cell biology are welcome, including mechanistic studies of embryonic stem cells; the reprogramming of cell fates; studies of mechanisms involved in regulating the differentiation stem cells towards specific cell fates; the developmental biology of tissue-specific stem and/or progenitor cells; the epigenetics, genomics and proteomics of stem cells, and the biology of cancer stem cells. We also welcome manuscripts that establish novel paradigms for clinical translation of cell-based therapies involving the use of stem cells. Only those manuscripts that are well designed and written, provide significant new insights, and explore a topic in-depth will be published. Manuscripts that report novel and significant findings will be given preference over confirmatory studies.
The Structural Biology section seeks original articles that address fundamental aspects of structural biology, which lead to either a better understanding of the functional/mechanistic properties of biologically important macromolecules or provide insight into pharmacological regulation of potential therapeutic targets. Manuscripts in this section will typically couple structural findings with additional experimental evidence (both - in vitro or in vivo) to support the conclusions made in the manuscript. EBM recognizes that structural biology is a diverse field and will welcome manuscripts that use various techniques, including but not limited to, X-ray crystallography, NMR, SAXS and Cryo-EM. If necessary, authors will be required to deposit coordinates to publically available databases (e.g. Protein Data Bank) and obtain an accession code. To support the quality of the structural information, authors are encouraged to include Section Descriptions (October, 2022) Page 7 validation reports when applicable. Manuscripts can include either high or low-resolution structural studies. Manuscripts that include molecular characterization of mechanisms using a variety of techniques are also acceptable. For example, coupling biophysical characterization with mutational analysis to define macromolecular assemblies. Submissions that are limited in scope to a single technique without supporting results are better suited for a different journal. This section will not accept manuscripts that are purely computational. However computational biology that supplements the structural findings is acceptable. Since EBM is a diverse journal with a broad readership, manuscripts should be written for a diverse audience. Authors are encouraged to design figures to properly convey their structural results for a general audience. For minireviews we encourage leaders in the field to discuss recent structural advances in their respective field and discuss future areas of exploration or areas that could benefit from a better molecular understanding.
The Synthetic Biology section aims to publish both original high-quality research articles and minireviews in the subject area of synthetic biology, broadly defined. Synthetic biology can be summarized as a field of research dedicated to the design of biological parts, systems, and devices across multiple length scales. We look forward to receiving manuscripts that either: (i) report engineering biology that can ultimately be used in industrial/technological/medicinal applications, (ii) exploit an “understanding by building” approach as a tool to increase our understanding of fundamental processes in nature, and/or (iii) provide insights into questions relating to the origins of life, and how molecular building blocks come together to enable life. Articles concerning both top-down and bottom-up approaches will be considered. Examples include metabolic engineering, biomolecular engineering, cell-free synthetic biology, bacterial/mammalian/plant synthetic biology, artificial cells, in vitro cell models, computational/modelling approaches, novel techniques, enabling technologies etc. Interdisciplinary submissions bridging the divide between the engineering, physical and life sciences are strongly encouraged.
The Systems Biology and MicroPhysiological Systems section recognizes both the breadth and complexity of biology, the need to strengthen the ties between biology, medicine, engineering and the physical sciences, the challenges of spanning both basic research and clinical medicine, and the opportunities presented by organs-on-chips and the microphysiological systems they enable. This section seeks manuscripts describing original research and minireviews that span multiple disciplines, provide new interdisciplinary perspectives to challenging problems, involve the application of new tools and techniques to biology and medicine, or the application of organs-on-chips and tissue chips to problems in systems biology, pharmacology, physiology, and toxicology. The desired focus of articles is that they are informative to all audiences within EBM and are not directed solely towards narrow topics in either biology, medicine, or physiology. This section serves as a venue where biologists and physicians can learn about the application of new technologies to biological or clinical problems, with a biology content that is more than just proof-of-concept of a new tool, as might be expected by a device- or instrument-oriented specialty journal. Similarly, engineers and physical scientists should view this section as a source of information on practical, even clinical, needs of systems biology and integrative physiology. We seek minireviews of the breadth of approaches to either a practical problem, such as the many means to measure cellular mechanical forces developed by living cells in vitro, or an in-depth discussion of a systems-physiology problem that has yet to be explored by physical scientists and engineers, for example, the complexity of how metabolism of a drug or toxin by one organ might affect other organs. Ideally, this section will serve as a meeting place for biologists, physicians, engineers, and physical scientists to join together to explore the intersections of their core Section Descriptions (October, 2022) Page 8 disciplines – an intersection best described as systems biology. As shown on the cover of this journal, systems biology and microphysiological systems together should advance the closing of the hermeneutic circle of biology, wherein knowledge of the whole informs our understanding of the parts, and where knowledge of the parts increases our understanding of the whole.
The Translational Research section is interested in research that connects or moves the study in one discipline to another. Particularly for biomedicine, translational research is the research that relates basic and clinical research to medical or industrial application. As such, it includes a wide range of biological, medical, chemical, pharmacological, engineering, and computational studies that aim at elucidating the mechanism of a biological or disease related pathological function/process, or applying such mechanistic understanding to the generation of new knowledge/strategies with clinical or industrial implication. We are interested in publishing original and high-quality research that meets the goal and definition of translational research as described above. This may include (not limited to) studies in the following example areas: (1) identification or characterization of a biological target or signaling pathway involved in a disease pathology or therapeutic invention; (2) discovery and development of novel therapeutic or diagnostic methods or agents with implications for clinical or industrial application; (3) study of the mechanism of action of currently used drugs or new experimental agents at the molecular, cellular or systems level; (4) clinical research for novel experimental therapeutics or new applications of existing drugs or that reveals mechanistic insight into a disease process or new targets or approaches for clinical intervention or prevention; (5) development of new tools or methods by chemical, engineering, nanotechnology or computational techniques that can be applied to study biology or human diseases; and (6) genetic, proteomic or systems biological study to reveal new markers, pathways or targets for clinical application. Reports of pure clinical methods, tools, procedures, or observations without molecular, cellular or systems investigation of mechanism or insight into new mechanism or target for clinical treatment or detection are not acceptable. Studies of alternative medicine without mechanistic investigations as described above are also not accepted. For chemical, computational or engineering studies of molecular systems, some biological or clinical results must be presented, or in the absence of such data, such molecular systems should have clear potential for biological or medical application.
Experimental Biology and Medicine (EBM) is a global, peer-reviewed journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. EBM provides both research and review articles as well as meeting symposia and brief communications. Articles in EBM represent cutting edge research at the overlapping junctions of the biological, physical and engineering sciences that impact upon the health and welfare of the world's population.
Topics covered in EBM include: Anatomy/Pathology; Artificial Intelligence/Machine Learning Applications to Biomedical Research; Biochemistry and Molecular Biology; Bioimaging; Biomedical Engineering; Bionanoscience; Cell and Developmental Biology; Clinical Trials; Endocrinology and Nutrition; Environmental Health/Biomarkers/Precision Medicine; Genomics, Proteomics, and Bioinformatics; Immunology/Microbiology/Virology; Mechanisms of Aging; Neuroscience; Pharmacology and Toxicology; Physiology and Pathophysiology; Population Health; Stem Cell Biology; Structural Biology; Synthetic Biology; Systems Biology and Microphysiological Systems; and Translational Research.
1. What do we publish?
1.1 Aims & Scope
Experimental Biology and Medicine is particularly appropriate for publication of papers that are multidisciplinary in nature, are of potential interest to a wide audience, and represent experimental medicine in the broadest sense of the term. However, manuscripts reporting novel findings on any topic in the realm of experimental biology and medicine are most welcome. We encourage submission of manuscripts that describe results of studies that require an interdisciplinary approach to biomedical issues.
Categories currently listed in EBM are: Anatomy/Pathology; Artificial Intelligence/Machine Learning Applications to Biomedical Research; Biochemistry and Molecular Biology; Bioimaging; Biomedical Engineering; Bionanoscience; Cell and Developmental Biology; Clinical Trials; Endocrinology and Nutrition; Environmental Health/Biomarkers/Precision Medicine; Genomics, Proteomics, and Bioinformatics; Immunology/Microbiology/Virology; Mechanisms of Aging; Neuroscience; Pharmacology and Toxicology; Physiology and Pathophysiology; Stem Cell Biology; Structural Biology; Synthetic Biology; Systems Biology and Microphysiological Systems; and Translational Research. For more information on these topics please click here to review the category descriptions. Authors should indicate their preference of category in the on-line submission form, although the final decision of reviewing Associate Editor and section Editorial Board rests with the Editor-in-Chief.
1.2 Article Types
Original Research: Manuscripts describing complete studies that are of high impact to the field will be published as Original Research. Manuscripts should be as concise as possible, yet sufficiently detailed to permit critical appraisal, and should generally not exceed 40 typed pages (including tables, figures and references). Unnecessary subdivision of a study into several manuscripts is not acceptable. Formatting should follow the requirements in the Submission Guidelines.
Brief Communications: Manuscripts describing focused studies that are concise and of high impact to a field will be published as Brief Communications. This format is intended for the presentation of scientifically sound and novel research in a clear and concise fashion. The body of the paper (text and references) should not exceed nine (9) pages of double-spaced text. Tables and Figures must also be kept to a minimum (no more than four). The Results and Discussion sections can be presented individually or combined into a single section. Otherwise, formatting should follow the requirements in the Submission Guidelines.
Minireviews: The journal publishes review articles under the section heading "Minireviews." Although there is no page limit, the reviews are generally short (~20 pages of double-spaced text with references). They should reflect the state-of-the-art of the area being reviewed and often include a brief history of the field. There is no need to include an exhaustive literature survey. Emphasis upon a particular hypothesis or point of view or upon the personal opinions or interpretation of the writer or upon the work of the writer's laboratory is appropriate, provided that this focus is clearly indicated in the paper. Most reviews are submitted in response to an invitation from the Editor-in-Chief and are subjected to the usual review process prior to publication. Unsolicited reviews require approval by the Editor-in-Chief before receiving peer review. Minireviews should not include Materials and Methods or Results sections. Otherwise, formatting should follow the requirements in the Submission Guidelines.
Comments: The Journal, at the Editor-in-Chief's discretion, will publish, under the section heading "Comments", letters or essays from readers discussing articles that have recently appeared in the Journal or other timely topics of interest to the Journal's readership. The author of a letter or essay which is published accepts full responsibility for the contents of the letter. Letters discussing a published article may for example include supporting information, clarifications, criticisms, corrections, alternate interpretations or perspectives. Such letters will be sent to the corresponding author of that article prior to publication. If the corresponding or other author wishes, her/his response will be published together with the original letter. At the discretion of the editor, essays or letters discussing controversial issues may be sent to persons representing alternative viewpoints who will be encouraged to provide responses. If the Editor decides to publish such responses, they will be sent to the original author for comments prior to publication. In some cases, the Editor-in-Chief may send a letter or essay for outside review prior to deciding whether to publish it. The Journal reserves the right to edit these communications without materially changing their meaning.
2. Editorial policies
2.1 Peer review policy
Only manuscripts of sufficient quality that meet the aims and scope of Experimental Biology and Medicine will be processed for review. Manuscripts are assigned to Global Editors based on the country of origin. Manuscripts from countries without Global Editors are assigned to the Editor-in-Chief. Impactful manuscripts deemed by the Global Editor to fall within the interests of the Journal's readership and to be written in clear, concise and grammatical English are assigned to an Associate Editor.
Manuscripts are assigned to Associate Editors based on subject category (see section 1.1). Authors should indicate their preference of category during the submission process. However, the final decision of reviewing Associate Editor and section rests with the Editor-in-Chief. If the reviewing Associate Editor determines that the manuscript has sufficient impact and scientific rigor, and the English language is suitable for review, then he/she will assign reviewers.
Generally, two reviewers will evaluate each manuscript on the basis of scientific rigor of the experimental design, adequacy of the data, validity of the conclusions, importance and originality of the studies, adequacy of the literature citations, clarity of the presentation, and interest to the Journal's readership. Manuscripts will be given a quality (priority) ranking by each reviewer. Those manuscripts with low priority rankings will not be accepted even though they may have been classed as generally acceptable. If reviewers differ significantly in their opinions, the decision will be based on the priority rankings and/or the opinion of an additional reviewer (arbiter). Normally, revised manuscripts are sent back to the original reviewers together with the authors' responses.
The reviewers' comments will be held in confidence except as follows: (a) the reviewers' comments may be sent, in whole or in part, to the corresponding author; (b) after revision, each reviewer's comments will be sent, in whole or in part, to the other reviewers of the manuscript: and (c) in the event that there is a significant difference in opinion between or among the reviewers, the manuscript may be sent to an additional reviewer (arbiter) together with the comments, in whole or in part, of the other reviewers. In all cases, anonymity of the reviewers will be maintained.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
2. Drafted the article or revised it critically for important intellectual content,
3. Approved the version to be published,
4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship. All contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship (http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html).
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support. Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and should be excluded from the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. Language polishing and copyediting services should NOT be included in the Acknowledgements.
2.4 Financial support
Experimental Biology and Medicine requires that all authors acknowledge all grant, contract and industrial support of the work in the published article and on-line submission form. All submitted articles must include a Funding section/statement in the Main Document (see Submission Guidelines).
2.5 Conflict of interest
Authors are required at the time of submission to disclose potential conflict of interests (eg., consultancies, stock ownership, equity interests, patent-licensing arrangements, lack of access to data, or lack of control of the decision to publish) in the on-line submission form. A YES answer to the Conflict of Interest question requires that additional details be provided in the online form and that a completed Conflict of Interest Disclosure form(s) be submitted with the manuscript files. Such information, unless already disclosed in the submitted manuscript, will be held in confidence while the paper is under review. If the manuscript is accepted for publication, any information on the potential conflict of interest not disclosed in the submitted article, including a lack of control of the decision to publish, will be inserted during typesetting. The corresponding author is responsible for obtaining signed forms from all authors that have a potential conflict of interest.
For guidance on conflict of interest statements, please see the ICMJE recommendations (http://www.icmje.org/recommendations/browse/roles-and-responsibilities/author-responsibilities--conflicts-of-interest.html#two). Guidelines for formatting the Declaration of Conflicting Interests section in the Main Document can be found in the Submission Guidelines.
2.6 Research ethics
Studies involving human subjects must conform to the ethical standards set by the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research; must have been reviewed and approved by the appropriate institutional Review Board (IRB); and must be presented in such a manner as to assure preservation of the anonymity of the subjects. It must be stated in the Materials and Methods section of the article that the study had been approved by the responsible IRB and that informed consent was obtained from research subjects or it must be explained why IRB review and /or informed consent were not required. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number in the Ethical Approval section in the Main Document (see Submission Guidelines).
It is the Journal's policy that all studies involving the use of animals be conducted in compliance with applicable laws and regulations as well as the principles expressed in the National Institutes of Health, USPHS, Guide for the Care and Use of Laboratory Animals, and that the studies be conducted on animals that were lawfully acquired. Use of animals must have been approved by the Institution's Animal Care and Use Committee (IACUC) and this must be stated in the Materials and Methods section of the article. If the study was conducted in a jurisdiction where such review is not required, this should be noted in the Materials and Methods section.
Experiments involving recombinant DNA must have been reviewed and approved as required by applicable laws and regulations.
2.7 Dual Submission
Manuscripts are accepted for review with the understanding that the same work has not been submitted or published elsewhere and, if accepted by the Journal, will not be submitted or published elsewhere. If evidence of dual submission is found, the manuscript will be rejected or, if published, retracted. Posting submitted material on a web site prior to publication may also be considered dual submission. If any material published previously is included, for clarity or other reasons, this should be indicated with appropriate citation in the manuscript. Contact the Editorial office at email@example.com if you require further information.
Experimental Biology and Medicine will accept submissions posted on non-profit preprint servers only if they are posted prior to submission on bioRxiv (https://www.biorxiv.org) or medRxiv (https://www.medrxiv.org). Preprints are defined as an author’s version of a research manuscript prior to formal peer review at a journal, which is deposited on a public server (as described in Preprints for the life sciences. Science 352, 899–901; 2016). Posting on any preprint server after submission, or a non-approved pre-print server prior to submission will be considered dual submission. If evidence of dual submission is found, the manuscript will be rejected or, if published, retracted.
Authors must provide the DOI for the preprint during the on-line submission process (Step 6: Details and Comments). If the paper is accepted by EBM, the author agrees to ask the preprint archive to include a link to the published article and its DOI.
As for all articles, the editors consider novelty when making manuscript decisions, and publication priority can be affected if significant publicity occurs before or during the peer-review process.
3. Publishing Policies
The knowing duplication of published work without appropriate attribution will not be tolerated. This policy covers all material, whether in the form of text, tables, figures or other exhibits, which has been published or is being considered for publication in another journal, and applies to the published work of the submitting author(s) as well as the work of other investigators.
Experimental Biology and Medicine and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
Three levels of plagiarism are covered by this policy, with progressively more severe sanctions: Level one: Limited duplication of text from the authors' own published work, with somewhat more relaxed stringency for materials and methods: In these cases, the manuscript will be returned to the authors with instructions to rewrite/rephrase the duplicated text, before publication of the submission may proceed. If the materials and methods are heavily duplicated, the authors could be advised to reference their published work, thereby shortening that section. Level two: Substantial duplication of an author's own work, or significant duplication of the work of others, will result in rejection of the manuscript or retraction after publication. Level three: Duplication of an author's own work so extensive that it could be considered an attempt to publish the same work twice (dual or redundant publication), or lifting of large chunks of text or data from the work of others, will result in rejection of the manuscript or retraction after publication and, in addition, contacting the appropriate officials at the author's institution.
Submitted manuscripts which, following the initial review, have a likelihood of eventual publication in EBM, will be evaluated by advanced plagiarism detection software, which systematically compares the manuscript against an extensive database of published literature and websites. If the software identifies possible plagiarism, further investigation will be conducted by the Associate Editor of the assigned section of EBM. Findings of potential plagiarism requiring one of the sanctions described above will be forwarded to the Editor-in-Chief for further review. Every effort will be made to conduct these reviews in a careful, fair and impartial manner, to avoid inappropriate imposition of sanctions. EBM urges submitting authors to avoid duplication either of their own work or that of others, and recommends authors evaluate their manuscripts with plagiarism-detecting software before submitting their work to EBM.
3.2 Contributor's publishing agreement
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Authors of accepted manuscripts will be required to assign copyright to the Society for Experimental Biology and Medicine (SEBM). For more information please visit the SAGE Author Gateway (https://uk.sagepub.com/en-gb/eur/contributor-agreement).
3.3 Open access and author archiving
Experimental Biology and Medicine offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website (https://uk.sagepub.com/en-gb/eur/sage-choice). For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies (https://uk.sagepub.com/en-gb/eur/copyright-and-permissions).
4. Publication charges
Authors are required to pay a part of the cost of publication in the form of an administrative fee of $1,000 per accepted article. There is no administrative fee for articles where the first or corresponding author is an SEBM member in good standing at the time of manuscript submission.
Authors lacking funding from grant or other sources may apply at the time of submission for a waiver of the administrative fee. Apply for a waiver of page charges on institutional letterhead at the time of submission. The request must be sent via email (firstname.lastname@example.org) and include a letter endorsed by a senior institutional official verifying that no funds are available for paying page charges. A waiver of page charges will not be granted once an initial decision has been rendered on the manuscript. Once a waiver has been approved and a paper published authors may not request a waiver for any future manuscripts.
5.1 SAGE Production
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Corrections should be kept to a minimum. Authors will be charged for excessive changes. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.
5.2 Online First publication
Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication.
5.3 Access to your published article
SAGE provides authors with online access to their final article. A link is provided allowing the author to download the article directly from the SAGE website and forward the link onto their co-authors.
5.4 Promoting your article
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work (https://uk.sagepub.com/en-gb/eur/promote-your-article). In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article (https://uk.sagepub.com/en-gb/eur/maximize-your-articles-impact-with-kudos)
|Steven R. Goodman, PhD||University of Tennessee Health Science Center, Memphis, TN, USA|
|Gordon Awandare, PhD||University of Ghana, Africa|
|Shaw-Jeng Tsai, PhD||National Cheng-Kung University Medical College, Taiwan|
|Nicola Conran, PhD||University of Campinas, Brazil|
|Farzin Farzaneh, PhD||King's College London, UK|
|Y James Kang, DVM, PhD||Regenerative Medicine Research Centre, Sichuan University West China Hospital, Chengdu, China|
|Aaron Ciechanover, MD/PhD||The Technion Institute, Israel|
|Russell Hulse, PhD||The University of Texas at Dallas, USA|
|Ian S. Zagon, PhD||Pennsylvania State University, USA|
|William Allen Banks, MD||VA Puget Sound Health Care System, USA|
|Lynda Bonewald, PhD||Indiana University School of Medicine, USA|
|Beverley Greenwood-Van Meerveld, PhD||The University of Oklahoma, College of Medicine, USA|
|Alexander V. Ljubimov, PhD, DSc,||Cedars-Sinai Med Ctr, Los Angeles, USA|
|Patricia J. McLaughlin, DEd||The Pennsylvania State University, USA|
|Artur Pasternak, MD, PhD||Jagiellonian University Medical College, Poland|
|Douglas F. Paulsen, PhD||Morehouse School of Medicine, USA|
|Ann M. Schreihofer, PhD||University of North Texas HSC, USA|
|Theodore Slotkin, PhD||Duke University Medical Center, USA|
|Huixiao Hong, PhD||US Food and Drug Administration, USA|
|Feixiong Cheng, PhD||Cleveland Clinic, USA|
|Xiaohui Fan, PhD||Zhejiang University, China|
|Ping Gong, PhD||US Army Corps of Engineers, USA|
|Ruili Huang, PhD||National Institutes of Health, USA|
|Fred Prior, PhD||University of Arkansas for Medical Sciences, USA|
|Paul Rogers, PhD||US Food and Drug Administration, USA|
|Tieliu Shu, PhD||East China Normal University, China|
|Wenming Xiao, PhD||US Food and Drug Administration, USA|
|Muriel W. Lambert, PhD||Rutgers New Jersey Medical School, USA|
|Brian Adams, PhD||The Brain Institute of America, USA|
|Robert M. Brosh Jr., PhD||National Institutes of Health, USA|
|James P. O’Connor, PhD||Rutgers New Jersey Medical School, USA|
|Bin Guo PhD||University of Houston, USA|
|Aleksander F. Sikorski, PhD||Regional Specialist Hospital, Poland|
|Howard J. Worman, MD||Columbia University, USA|
|Shuliang Jiao, PhD||Florida International University, USA|
|Kamran Avanaki, PhD||University of Illinois at Chicago, USA|
|Zygmunt (Karol) Gryczynski, PhD||Texas Christian University, USA|
|Hong Liu, PhD||University of Oklahoma, USA|
|Kate Luby-Phelps, PhD||University of Texas Southwestern Medical Center, USA|
|Qingming Luo, PhD||Huazhong University of Science & Technology, Wuhan, China|
|Xinmai Yang, PhD||The University of Kansas, USA|
|Xincheng Yao, PhD||University of Illinois at Chicago, USA|
|Baohong Yuan, PhD||University of Texas at Arlington, USA|
|Weizhao Zhao, PhD||University of Miami, Florida, USA|
|Horst A. von Recum, PhD||Case Western Reserve University, USA|
|Stuart L. Cooper, PhD||The Ohio State University, USA|
|F. Kurtis Kasper, PhD||University of Texas HSC at Houston, USA|
|Angela Pannier, PhD||University of Nebraska, USA|
|Adam Perriman, PhD||University of Bristol, UK|
|Juan Andres Melendez, PhD||SUNY – Polytechnic Institute, USA|
|Nathaniel C. Cady, PhD||SUNY Polytechnic Institute, USA|
|Hassan A. N. El-Fawal, PhD||American University in Cairo, Egypt|
|Mark Kester, Ph.D.||University of Virginia, USA|
|Jonathan Lovell, PhD||State University of New York at Buffalo, USA|
|Ya-Ping Sun, PhD||Clemson University, USA|
|M. Silvina Tomassone, PhD||Rutgers University, USA|
|Siyang Zheng Ph.D.||Carnegie Mellon University, USA|
|Warren E. Zimmer, PhD||Texas A&M University, USA|
|David A. Dean, PhD||University of Rochester, USA|
|Leszek Kotula, MD||SUNY Upstate Medical University, USA|
|William E. Miller, PhD||University of Cincinnati College of Medicine, USA|
|Harold Ivan Saavedra PhD||Ponce Health Sciences University, Puerto Rico|
|Yigang Wang, M.D., Ph.D., F.A.H.A.||University of Cincinnati College of Medicine, USA|
|Susanne Wells, PhD||University of Cincinnati College of Medicine, USA|
|Guiseppe Pizzorno, PharmD||University of Tennessee HSC, USA|
|Yehoshua C. Levine, MD||University of Tennessee HSC, USA|
|Daniel Vaena, MD||University of Tennessee HSC, USA|
|Nancy Turner, PhD||Michigan State University, USA|
|Clint Allred, PhD||University of North Carolina at Greensboro, USA|
|Samuel Dagogo-Jack, MD||University of Tennessee, USA|
|Gabrielle Page-Wilson, MD||Columbia University, USA|
|Eugene Sobngwi, MD, MPh, PhD||University of Yaounde, Cameroon|
|Weiqun (George) Wang, PhD||Kansas State University, USA|
|Malcom Watford, PhD||Rutgers University, USA|
|Chia Shan Wu||Texas A&M University|
|William Slikker, Jr., PhD||US Food and Drug Administration, USA|
|Ritchie Feuers, PhD||US Food and Drug Administration, USA|
|Gary Steven Friedman, MD||Pfizer, Inc., USA|
|Donald J. Johann Jr., MD||University of Arkansas for Medical Sciences, USA|
|Donald R. Mattison, MD||Risk Sciences International/University of Ottawa, Canada|
|Donna L. Mendrick, PhD||US Food and Drug Administration, USA|
|John-Michael Sauer, PhD||Critical Path Institute, USA|
|Cheng Wang, MD, PhD||US Food and Drug Administration, USA|
|Paul Brent Watkins, MD||University of North Carolina, USA|
|Sulev Koks, MD, PhD||The Perron Institute for Neurological and Translational Science, Australia|
|Mark Geraci, MD||University of Pittsburgh, USA|
|Stephen J. Glatt, PhD||SUNY Upstate Medical University, USA|
|Momar Ndao, DVM, PhD||Montreal General Hospital, Canada|
|Paul Keith Potter, PhD||Oxford Brookes University, UK|
|John Peter Quinn, PhD||The University of Liverpool, UK|
|Heinrich Roder, PhD||Fox Chase Cancer Center, USA|
|Giovanni Stracquadanio, PhD||University of Edinburgh, UK|
|Andrea Doria||University of Padova, Italy|
|Mariele Gatto PhD||University of Padova, Italy|
|Farzin Farzaneh, PhD||King's College London, UK|
|Kam Man Hui, PhD||National Cancer Centre Singapore, Singapore|
|Francois Villinger, PhD||University of Louisiana at Lafayette, USA|
|Shigemi Matsuyama, PhD, DVM||Case Western Reserve University, USA|
|Ricki Jean Colman, PhD||University of Wisconsin, Madison, USA|
|Ao-Lin Allen Hsu,, PhD||University of Michigan Medical School, USA|
|Akhiro Ikeda, PhD, DVM||University of Wisconsin-Madison, USA|
|Masaru Miyagi, PhD||Case Western Reserve University, USA|
|Vincint M. Monnier, MD||Case Western Reserve University, USA|
|Michael Lehman, PhD||Kent State University, USA|
|Lique Coolen||Kent State University|
|Terrence Deak, PhD||Binghamton University, USA|
|Max L. Fletcher, II, PhD||University of Tennessee Health Science Center, USA|
|James Hewett, PhD||Syracuse University, USA|
|Sandra J. Hewett, PhD||Syracuse University, USA|
|Sandra Mooney, PhD||University of North Carolina, USA|
|Gregg D. Stanwood, PhD||Florida State University, USA|
|Mingqing Xu, PhD||Shanghai Jiao Tong University, China|
|Santosh Kumar||University of Tennessee Health Science Center|
|Matthias Barton, MD||University of Zurich, Switzerland|
|Guzel Bikbova, MD/PhD||Chiba Univesrity, Japan|
|Pawel Brzuzan, PhD||University of Warmia and Mazury in Olsztyn, Poland|
|Laetitia Dou, PhD||Aix-Marseille Universite, France|
|Jianxiong Jiang, PhD||University of Tennessee Health Science Center, USA|
|Youngmi Jung, PhD||Pusan National University, Korea|
|Li-Fu Li, MD/PhD||Chang Gung Memorial Hospital and Chang Gung University, Taiwan|
|Samuel Gnana Prakash Vincent, PhD||Manonmaniam Sundaranar University, India|
|Jonathan Henry Shannahan, PhD||Purdue University, USA|
|Martin Sterba, PhD||Charles University Faculty of Medicine in Hradec Kralove,Czech Republic|
|Manish K. Tripathi||University of Texas Rio Grande Valley|
|Chaowu Xiao, PhD||Health Canada, Canada|
|Wuxiang Xie, PhD||Peking University Clinical Research Institute, China|
|Qihe Xu, MD/PhD||Kings College London, UK|
|Robert T. Mallet, PhD||University of North Texas, USA|
|R. Todd Alexander, MD/PhD||University of Alberta, Canada|
|Frantisek Kolar, PhD||Academy of Sciences of the Czech Republic, Czech Republic|
|Rong Ma, MD/PhD||University of North Texas Health Science Center, USA|
|Gabor Joseph Tigyi, MD, PhD||University of Tennessee Health Science Center, USA|
|Shaw-Jeng Tsai, PhD||National Cheng-Kung University Medical College, Taiwan|
|Samuel Verges, PhD||Grenoble Alps University, France|
|Tobias Wang, PhD||Aarhus University, Denmark|
|Lei Xi, MD||Virginia Commonwealth University, USA|
|Shaohua Yang, MD, PhD||University of North Texas Health Science Center, USA|
|Chunyu Zeng, MD||The Third Military Medical University, Chongqing City, China|
|Manish K. Tripathi||University of Texas Rio Grande Valley|
|Ashish Joshi||City Univeristy of New York|
|Jian Feng, PhD||State University of New York at Buffalo, USA|
|Vania Broccoli, PhD||San Raffaele Scientific Institute, Milano, Italy|
|Jose Cibelli, DVM||Michigan State University, USA|
|Guoping Fan, PhD||University of California, Los Angeles, USA|
|Meri T. Firpo, PhD||Memphis Meats, USA|
|Antonis Hatzopoulos, PhD||Vanderbilt University, USA|
|Yoon-Young Jang, MD, PhD||Johns Hopkins University School of Medicine, USA|
|Dan S. Kaufman, MD||University of California, San Diego, USA|
|Mark Mercola, PhD||Stanford University, USA|
|Steven Stice, PhD||University of Georgia, USA|
|Chun-Li Zhang, PhD||UT Southwestern Medical Center, USA|
|Thomas B. Thompson, PhD||University of Cincinnati College of Medicine, USA|
|Andrew P. Hinck, PhD||University of Pittsburgh, USA|
|James R. Horn, PhD||Northern Illinois University, USA|
|Douglas John Kojetin, PhD||Scripps Florida, USA|
|Rhett A. Kovall, PhD||University of Cincinnati College of Medicine, USA|
|Vincent C. Luca, PhD||Moffitt Cancer Center & Research Institute, USA|
|Rick Page, PhD||Miami University, USA|
|Tara L. Deans, PhD||University of Utah, USA|
|Tom Ellis||Imperial College London|
|Neha Kamat||Boston University|
|Ahmad Khalil||Boston University|
|Jenny C. Mortimer||Lawrence Berkeley National Laboratory, USA|
|Kevin Solomon||University of Delaware|
|Andre Levchenko, PhD||Yale Systems Biology Institute, USA|
|Rashid Bashir, PhD||University of Illinois, Urbana-Champaign, USA|
|Richard A. Gray, PhD||Food and Drug Administration, USA|
|Salman K. Khetani, PhD||University of Illinois at Chicago, USA|
|Deok-Ho Kim, PhD||Johns Hopkins University School of Medicine, USA|
|Philip R. LeDuc, MD||Carnegie Melon University, USA|
|Peter Loskill, PhD||University Tübingen, Germany|
|D. Lansing Taylor, PhD||University of Pittsburgh, USA|
|Jing An, MD, PhD||University of California San Diego, USA|
|Roy Baynes, PhD||Merck Inc., USA|
|Yukai He, MD, PhD||Augusta University, USA|
|Hyacinth I. Hyacinth, MD, PhD, MPH||University of Cincinnati, USA|
|Chulso Moon, MD, PhD||HJM Research Foundation, USA|
|Esther A. Obeng, MD, PhD||St. Jude Children’s Research Hospital, USA|
|Jeffrey Schlom, PhD||National Cancer Institute, USA|
|Vivien Sheehan, MD/PhD||Emory University School of Medicine, USA|
Please read the Submission Guidelines below before visiting the Journal’s submission site (https://mc.manuscriptcentral.com/ebm) to submit your manuscript. These instructions comply with the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE). Any correspondence, queries or requests for additional information should be sent to the Experimental Biology and Medicine Editorial Office (email@example.com).
In 2023, Experimental Biology and Medicine will be transitioning to an online only publication model. The Society for Experimental Biology and Medicine is making this important transition to reduce our impact on the environment and allow for greater investment in benefits for authors and readers. To facilitate the change, articles submitted after October 1 will be subject to a flat administrative fee.
Manuscripts that do not conform to these guidelines will be unsubmitted and returned to the authors for modification. To reduce the time to first decision, authors should verify that their submission (online and all files) includes the following:
- Title, author names and author order in the online form exactly match those on the Title page in the Main Document file
- Valid email address for all authors
- Completed Mandatory Submission Form (see section 1.7)
- Main Document (word file only) formatted as instructed in section 1.2.
- Table files submitted and formatted as instructed in section 1.3.
- Figure files submitted and formatted as instructed in section 1.4.
- A single supplementary for review file formatted as instructed in section 1.6.
- Verification that the information in the PDF-generated for reviewers/editors is complete and in the correct order, and that all text in figures is legible at 100% (see section 2.3)
1.1 Cover Letter
1.10 Revised manuscripts
2.1 User Accounts
2.3 Manuscript PDF
The cover letter is important as it helps the Editor in his/her preliminary evaluation. The letter should indicate why you think the paper is suitable for publication, how your paper is innovative, provocative, timely, and of interest to a broad audience. The letter should list any paper on related topics by any of the authors that have been published within the past year or that are in review or in press. The letter must state that the non-signing author(s) have read and approved the manuscript. The cover letter can be copied/pasted or attached as a file in the Cover Letter section of the online submission form (Step 6: Details and Comments).
The Main Document must be a word file formatted using 1 inch margins, 11 pt or larger font size, double-spacing, left-aligned text, and single-column text. Do not use numbers/letters in headings or subheadings.
Trade name, popular name or abbreviation when first used must be preceded by the chemical, scientific or technical name. Trade names should begin with a capital letter. Structural formulas of chemicals should be used only when absolutely necessary. Symbols and abbreviations should be those currently in use. Authors should not create new abbreviations and acronyms. Lists of abbreviations are not permitted. All measurements should be expressed in SI units.
For original research and brief communication articles the Main Document file should include the following sections in this order: Title Page, Abstract, Keywords, Impact Statement, Introduction, Materials and Methods, Results, Discussion, Authors’ Contributions, Acknowledgements (if applicable), Declaration of Conflicting Interests, Ethical Approval (if applicable), Funding, Figure Legends and References. In brief communications, the Results and Discussion sections can be combined.
Minireviews should contain the following sections in this order: Title Page, Abstract, Keywords, Impact Statement, Introduction, main text, Authors’ Contributions, Acknowledgements (if applicable), Declaration of Conflicting Interests, Funding, Figure Legends and References.
Title page: The Title page should be the first page of the Main Document and include the following information: full title of the manuscript, a short running title, the author(s) name(s), the author(s) affiliation(s) (including postal/zip codes) and corresponding author contact information (name, postal address and email address).
The title should be a declarative statement of key findings and should be limited to 15 words. Use of abbreviations in the title is not permitted.
Do not include degrees in the list of authors.
The manuscript title and author information (names/order) on the Title page must exactly match the information in the online submission form.
Abstract: An abstract of no more than 300 words should be placed on the page 2 of the Main Document and formatted as a single paragraph. Structured abstracts with subheadings are not permitted. The abstract should be copied/pasted in Abstract section of the online form (Section 1: Type, Title and Abstract).
Impact Statement: An Impact Statement is required for all submissions. Your impact statement will be evaluated by the Editor-in-Chief, Global Editors, and appropriate Associate Editor. For your manuscript to receive full review, the editors must be convinced that it is an important advance in for the field. The Impact Statement is not a restating of the abstract. It should address the following:
- Why is the work submitted important to the field?
- How does the work submitted advance the field?
- What new information does this work impart to the field?
- How does this new information impact the field?
The Impact statement should be no more than 150 words and formatted as a single paragraph without questions. Lists are not permitted. The Impact Statement will be included as a boxed statement on the first page of the article, separate from the Abstract. The Impact statement should be copied/pasted in the Impact Statement section of the on-line form (Section 1: Type, Title and Abstract).
Authors Contributions: Authors must include a statement that specifies the actual contribution of each co-author to the completed work. The “Authors’ Contributions” statement should be placed immediately after the Discussion/Conclusions and formatted as a single paragraph. For example: "All authors participated in the design, interpretation of the studies and analysis of the data and review of the manuscript; MPV, MNS, KAM, and YZ conducted the experiments, RJS supplied critical reagents [or animals] (specify), RAS and WEZ wrote the manuscript, and XYZ contributed [other] (specify)." Full names are not permitted.
Acknowledgments: Individuals whose contribution does not reach the level required for their inclusion as an author should be acknowledged in the traditional way, with their full names(s) given. For example, "The authors thank Dr. John Doe for advice in statistical analysis". The corresponding author must verify that all individuals who made contributions to this study are included either as authors or are acknowledged at the end of the paper.
Declaration of Conflicting Interests: Authors are required at the time of submission to disclose potential conflict of interests (eg., consultancies, stock ownership, equity interests, patent-licensing arrangements, lack of access to data, or lack of control of the decision to publish) in the on-line submission form (see section 2.5). If no conflict exists, please state that “The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article”.
Ethical Approval (if applicable): For studies involving human subjects, provide the full name and institution of the review committee.
Funding: The funding agency(s) should be written out in full, followed by the grant number in square brackets, see following example: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Medical Research Council [grant number xxx].
Multiple grant numbers should be separated by comma and space. Where the research was supported by more than one agency, the different agencies should be separated by semi-colon, with “and” before the final funder. For example: This work was supported by the Trust [grant numbers xxxx, yyyy]; the Natural Environment Research Council [grant number zzzz]; and the Economic and Social Research Council [grant number aaaa].
Where no specific funding has been provided for the research authors should state tha: “This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors”.
Figure Legends: Legends for figures should be placed before the References in the Main Document. Legends for supplementary figures should be included in the supplementary files and NOT in the Main Document. Legends should contain sufficient experimental detail to permit the figures to be interpreted without reference to the text.
References: Extensive citation should be avoided, if possible, while adhering to the applicable conventions of the scientific community. Authors are responsible for verifying citations against the original source material, and for obtaining permission to reproduce from the appropriate sources cited in the text. Citation of non-English and non-peer-reviewed publications is not permitted. "Personal communication", "unpublished", "submitted" and references with DOIs only must be excluded from the references.
References should be cited numerically in order of appearance in the text using superscript numerals. The references section should be formatted as shown below (ENDNOTE template Experimental Biology and Medicine (Maywood)):
Zhang X, Wang J, Fan Y, Yang L, Wang L, Ma J. Zinc supplementation attenuates high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelial cells. Biol Trace Elem Res 2012;150:229–35
Weatherall D, Clegg J. The molecular pathology of the thalassaemias. The Thalassaemia Syndromes, 4th ed. Oxford: Wiley-Blackwell, 2001, pp. 133–91
Tables should not duplicate information given in the text, numbered with Arabic numerals and cited consecutively in the text. Each table should be titled and double-spaced on a separate page. The title of each table should clearly indicate the nature of the contents, and sufficient experimental detail should be included in footnotes in the table to permit the reader to interpret the results without reference to the text. Units must be clearly indicated for each of the entries in the table.
Tables should be submitted as individual word files (1 table/file), with all columns contained on a single page. Tables should be uploaded/submitted in sequential order immediately following the Main Document. Filenames should use the following template where X is the table number: Table X.
All figures should be cited consecutively by Arabic numerals in the text. Figures should be submitted as individual word, jpeg, tiff or ppt files (1 figure/file) in such form as to permit photographic reproduction without retouching or redrawing. Units should be clearly indicated in the figures themselves. The lettering should be large enough to allow a reduction of two thirds. In addition, all text must be legible at 100% (i.e. without zooming/enlargement) in the PDF generated for reviewers and editors. Panels with micrographs/photographs must include at least one scale bar and a numerical definition for the scale bar within the figure legend in the Main Document. Magnification is NOT an appropriate unit for scale. Do not include legends in the figure files.
Figures should be uploaded/submitted in sequential order immediately following the Tables, or Main Document if there are no tables. Filenames should use the following template where X is the figure number: Figure X. EBM does not accept PDFs for figure files.
Figures supplied in color will appear in color online regardless of whether or not these illustrations are reproduced in color in the printed version. Information regarding color reproduction in print, will be provided after manuscripts are accepted.
Guidelines to assist authors prepare statistical data for publication can be found in the EBM Statistical Guidelines. These guidelines are not a substitute for the detailed guidance required to design a study or perform a statistical analysis.
Supplementary material relevant to scientific review should be uploaded/submitted in a single Supplementary for Review file formatted as a PDF. The Supplementary for Review file is available to reviewers/editors. If a manuscript is accepted, this file is available for download online as provided without modification or typesetting by the publisher.
Supplementary material that is not essential for scientific review should be uploaded/submitted as a Supplementary Not for Review file. These files are available to editors and administrative staff only; they are not available to reviewers or readers. The Mandatory Submission form (required), Copyediting Certificate (if applicable), and Conflict of Interest Disclosure form (if applicable) should be uploaded/submitted as Supplementary Not for Review files and be the final manuscript files. Filenames should include the name of the form.
A completed Mandatory Submission Form is required for all submissions. Authors should sign in English in the same order as on the manuscript title page. Computer generated signatures are NOT accepted. Multiple pages are acceptable, but all pages should be uploaded/submitted in a single Supplementary Not for Review file at the end of the manuscript files.
A YES answer to the Conflict of Interest question in the on-line form requires the submission of completed Conflict of Interest Disclosure Form(s). All pages/forms should be uploaded/submitted in a single Supplementary Not for Review file after the Mandatory Submission form.
If English is not your native language, you may find it helpful to obtain assistance in writing your papers before submission. This may not only save time in the review process but also increase the effectiveness of your submission. Quality of written English is judged by the Editor-in-Chief, Global Editors, and appropriate Associate Editor. They must be convinced that the quality of written English is sufficient for your manuscript to receive full review. EBM offers low-cost English services for authors (http://www.EBMEnglishServices.squarespace.com).
A YES answer to the copyediting question in the on-line submission form requires that a copy of the editing certificate be submitted as a Supplementary Not for Review file after the Mandatory Submission form, or Conflict of Interest form (if applicable).
When, as a result of reviewers' comments, it is necessary to revise a manuscript, it is recommended that authors submit the revised manuscript within the time-frame allotted in the decision letter. Longer delays may result in the revised manuscript receiving a lower priority score. Extensions require approval by the Associate Editor and should be requested prior to the due date as the online submission system will not permit submission if the revision option has expired. Journal policy permits only ONE extension. Delays in excess of 60 days require submission as a new manuscript.
Revised submission must include a detailed response to the decision letter for the previous version. The response letter should be uploaded/submitted during the online submission process (Step 1: View and Respond to Decision Letter). Do not include the response letter in the manuscript files. In addition, modifications in the manuscript files must be denoted using red text. Do not use track-changes, highlighted/underlined/strike-out text or comments to denote modified text.
Experimental Biology and Medicine is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts (https://mc.manuscriptcentral.com/ebm). For further guidance on submitting your manuscript online please visit http://mchelp.manuscriptcentral.com/gethelpnow/.
Before creating a new user account, please verify that you do not already have an account in the system. If you have reviewed or authored for the Journal in the past, it is likely that you will have an account in the system.
As part of the submission process you will be required to state that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal, that it is not being considered for publication elsewhere, that it has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
You will be asked to provide valid email addresses, contact details, and academic affiliations for all co-authors and identify who is to be the corresponding author. You will also be asked to provide an Abstract, keywords, an Impact statement, Funding information, and Conflict of Interest information. These details must match what appears in the Main Document file. You will also be asked to select a section/category and provide information regarding copyediting and membership in the Society for Experimental Biology and Medicine. You must also provide information regarding recommended and/or opposed reviewers. Finally, you will be asked to verify that your submission meets all guidelines outlined in these Instructions.
The submission system will generate a PDF for reviewers. Please review this file carefully and ensure your submission documents have been properly converted, as this is the ONLY file provided to reviewers.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
If you do not already have an ORCID iD please visit https://orcid.org.
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway (https://uk.sagepub.com/en-gb/eur/copyright-and-permissions).